Navigation Links
InterMune Announces Start of Phase 1b Trial of ITMN-191
Date:9/26/2007

F) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1a, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information. InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.

Factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the SEC on March 30, 2007 (the "Form 10-K") and other periodic reports filed with the SEC, including the following: (i) risks related to the long, expensive and uncertain clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues or delays in anticipated timing of the regulat
'/>"/>

SOURCE InterMune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
2. InterMune Presents Research on ITMN-191 in Hepatitis C at EASL Annual Meeting
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Sygnis Pharma AG announces date for presentation of clinical results
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  PANTHERx Specialty Pharmacy announced today that it ... a Washington, DC -based health ... the health care industry. Logo - ... accreditation process demonstrates a commitment to quality services ... processes through benchmarking organizations against nationally recognized standards. ...
(Date:9/2/2014)... Actavis plc (NYSE: ACT ) ... (FDA) has accepted for filing Actavis, New Drug Application ... of diarrhea and abdominal pain in men and women ... for eluxadoline has been granted priority review status by ... "The NDA filing of eluxadoline marks an ...
(Date:9/2/2014)... , Sept. 2, 2014  Boston Scientific Corporation ... previously announced agreement to purchase the Interventional business ... of Boston Scientific to offer physicians and healthcare ... treat challenging vascular conditions. The addition ... innovative technologies supports the Boston Scientific strategy to ...
Breaking Medicine Technology:PANTHERx Specialty Pharmacy Applying for URAC Specialty Pharmacy Accreditation 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 2Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 3Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 4Boston Scientific Closes Acquisition Of Interventional Business Of Bayer AG 5
... DEERFIELD, Ill. , April 28 ... and its wholly owned subsidiary, Takeda Pharmaceuticals North America, ... of eight defendants in patent infringement litigation brought against ... Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl) and ACTO ...
... Texas , April 27 Lexicon Pharmaceuticals, ... on discovering and developing breakthrough treatments for human disease, announced ... presentations on results from its Phase 2 clinical study with ... (IBS) at Digestive Disease Week (DDW) 2010 in New ...
Cached Medicine Technology:Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 2Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 3Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 4Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 5Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 6Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 7Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S. 8Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week 2Lexicon to Present Phase 2 Clinical Data for IBS Drug Candidate at Digestive Disease Week 3
(Date:9/2/2014)... 02, 2014 With recent expansions to their ... to create a consistent look or specific ambiance that tells ... floor you walk on and the chair you sit in, ... wood designs. , “We’re excited to offer a more ... It saves time, adds consistency, and let’s not forget celebrates ...
(Date:9/2/2014)... Cleveland, Ohio (PRWEB) September 02, 2014 ... Cellulon® Polyurethane technology to reduce discomfort and fatigue by ... flooring. Using an eco-friendly, renewable bio-foam core, these anti-fatigue ... in the USA. According to a study by the ... showing a significant difference in reducing spinal compression and ...
(Date:9/2/2014)... white pill may help scientists learn why patients with ... even if their lungs are relatively healthy. , ... Revatio to treat pulmonary hypertension and Viagra for erectile ... antioxidants will help them identify the root of the ... patients. , "We want to understand why these ...
(Date:9/2/2014)... of opioid-involved overdoses has become an increasing concern to ... the New York City Department of Health and Mental ... 2011 was nearly triple the number of such deaths ... to a dramatic rise in nonmedical prescription opioid (PO) ... in heroin use among youth who transitioned from POs ...
(Date:9/2/2014)... 2014In a new guideline, the Society for Maternal-Fetal Medicine ... in pregnancy. , "There is no evidence that ... of Delaware Center for Maternal and Fetal Medicine and ... is evidence that bed rest can be harmful for ... five women are placed on bed rest during their ...
Breaking Medicine News(10 mins):Health News:Pioneer Millworks Now Offering Products Beyond Reclaimed Wood Flooring 2Health News:New Eco-Pro Premium Anti-fatigue Mats from Martinson-Nicholls Prevent Fatigue and Discomfort for Standing Workers 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:NYC teens and young adults who abuse prescription at high risk for overdose 2Health News:NYC teens and young adults who abuse prescription at high risk for overdose 3Health News:SMFM releases paper on activity restriction in pregnancy 2
... saves a life. Saturday, April 25 is World Malaria Day. , ... ... teaming up with the United Nations Foundation and its Nothing But Nets ... his New Look Foundation, Raymond and the UN Foundation will provide opportunities ...
... | About 400 cancer therapy specialists from 100 countries ... week in Vienna at an IAEA event to discuss modern ... Conference on Advances in Radiation Oncology (ICARO) will start on ... the Vienna International Center. , All sessions of the ...
... Medical Technologies, Inc. (Nasdaq: PMTI ), a leading ... hold its quarterly conference call of its 2009 first quarter ... Eastern Time. If you would like to participate, please call ... The telephone replay will be available one hour after the ...
... Addicts, even those who have been abstinent for long ... memories of prior drug use. For example, exposure to ... a contextual memory can increase their craving for the ... study in the April 15th issue of Biological Psychiatry ...
... CINCINNATI, April 23 Kendle (Nasdaq: KNDL ... quarter 2009 financial results after the market closes on ... telephone conference call and simultaneous webcast on Thursday, May ... answer session will follow.(Logo: http://www.newscom.com/cgi-bin/prnh/20080923/CLTU095LOGO ...
... PALO ALTO, Calif., April 23 Percutaneous Systems, Inc. ... Accordion CoAx(TM) Stone Control Device, the newest member ... tools, at the upcoming annual meeting of the American ... Chicago, Illinois.The Accordion CoAx Stone Control Device is an ...
Cached Medicine News:Health News:IAEA conference to focus on new techniques in cancer treatment 2Health News:Palomar Medical Technologies to Host First Quarter 2009 Financial Results Conference Call and Webcast on April 30, 2009 2Health News:Treating addiction by eliminating drug-associated memories 2Health News:Kendle Announces First Quarter 2009 Earnings Conference Call and Webcast 2Health News:PercSys Introduces Accordion CoAx(TM) Stone Control Device for Facilitating Percutaneous Kidney Stone Treatments 2Health News:PercSys Introduces Accordion CoAx(TM) Stone Control Device for Facilitating Percutaneous Kidney Stone Treatments 3
... DTX Series Multimode Detectors provide unmatched ... of application and automation needs. Capable ... measurements on the same instrument, the ... instruments or can be integrated seamlessly ...
... PCR, cDNA and Oligonucleotides The Tecan ... a variety applications that are quantified by Fluorescence, ... handle assays in Microplate formats from 6 ... Cuvettes Independent whether you have to ...
... Designed for Ultra High Throughput Screening ... assay detection performance. Allows for smooth ... assay development by sharing all the ... HT, fluorescence intensity, fluorescence polarization, time-resolved ...
... system used to detect and quantitate contaminants, ... cell protein, bovine contaminants (e.g., BSA, IgG, ... any unique protein that can be bound ... and plasmid copy number. The system reduces ...
Medicine Products: